<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02200237</url>
  </required_header>
  <id_info>
    <org_study_id>CT-EV-21</org_study_id>
    <nct_id>NCT02200237</nct_id>
  </id_info>
  <brief_title>A Clinical Study for Inactivated Vaccine Against EV71</brief_title>
  <acronym>EV71</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Vaccine Biologics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Vaccine Biologics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine in
      health children and infants aged from 2 months to &lt;12yrs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate overall safety of EV71 vaccine in children, throughout the study period</measure>
    <time_frame>2 years after study initiation</time_frame>
    <description>Occurrence of overall adverse events and serious adverse events during the entire period of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunogenicity, serum neutralizing antibody titers humoral immune response, induced by candidate vaccine</measure>
    <time_frame>2 years from study initiation</time_frame>
    <description>To evaluate the immunogencity in terms of
Geometric mean titer (GMT) of EV71 neutralizing antibody titers
Post-vaccination-to-pre-vaccination GMT ratio of EV 71 neutralizing antibody titers
Seropositivity rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Enterovirus 71 Human</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate Buffer Saline with adjuvant aluminium phosphate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EV71 with adjuvant aluminium phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 Î¼g/0.5ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 with adjuvant aluminium phosphate</intervention_name>
    <description>Two arms, EV71 with aluminium phosphate</description>
    <arm_group_label>EV71 with adjuvant aluminium phosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate Buffer Saline with adjuvant aluminium phosphate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Healthy children and infants aged from 2 months to less than 12 years as established
             by medical history and clinical examination

          2. The subjects' guardians are able to understand and sign the informed consent

        Main Exclusion Criteria:

          1. Subject with previous known exposure to EV71.

          2. Subject with a history of herpangina or hand, foot and mouth disease associated with
             enterovirus infection in the past 3 months.

          3. Subject who was diagnosed with a significant neurological, pulmonary, cardiovascular,
             hematological, hepatic or renal disorder.

          4. Use of any investigational/non-registered product (including drug, vaccine and
             invasive medical device) within 30 days prior to vaccination or planned use during
             study period.

          5. Subject with any confirmed or suspected autoimmune disorder, or immunodeficiency

          6. Use of immunoglobulins or any blood products within 3 months prior to vaccination or
             planned use during the whole study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Min Huang, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang-Guang Memorial Hospital Lin-Kou</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hosptial</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2014</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EV71 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

